![[logo] HealthTree Foundation](https://static.healthtree.org/icons/icon_spinner.svg){kind=icon}
![[logo] HealthTree Foundation](https://static.healthtree.org/logo_icon_only.svg){kind=icon}
Showing 25 trials matching your filters.
Study of DISC-0974 in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Und... Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm Ruxolitinib in Thrombocythemia and Polycythemia Vera Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase M... Open Label Phase 2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythe... A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults ... A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced My... Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syn... A Study to Evaluate INCA033989 Administered in Participants With Myeloproliferative Neoplasms A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants W... Study of Canakinumab in Patients With Myelofibrosis Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Sign... Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Ph... INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Ane... A Safety and Tolerability Study of Jaktinib An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relap... Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 12... A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017) An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Rux... A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasm...
This phase 1b/2a open-label study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of DISC-0974 as well as categorize the effects on anemia response in subjects with myelofibrosis or myelodysplastic syndrome and anemia.
DRUG: DISC-0974
This is a prospective phase I dose-escalation study, with the primary objective to access the MTD and find the RP2D of talazoparib, given in combination with standard of care dosing of pacritinib.
DRUG: Talazoparib
DRUG: pacritinib
This phase II clinical trial evaluates whether a modified modality of conditioning reduces treatment-related mortality (TRM) in patients who undergo a hematopoietic stem cell transplant (HSCT) for a hematological malignancy. HSCT is a curative therap...
PROCEDURE: Hematopoietic Cell Transplantation
DRUG: Mycophenolate Mofetil
DRUG: Tacrolimus
DRUG: Cyclophosphamide
RADIATION: Total-Body Irradiation
PROCEDURE: Donor Lymphocyte Infusion
DRUG: Fludarabine
DRUG: Melphalan
The primary objective of this study is to assess the safety and tolerability of administrating mutated-CALR peptide Vaccine to patients with MPN. The researchers plan to enroll 10 patients over a 12 month period. Maximum length of participation in 80...
DRUG: Peptide-based vaccine
DRUG: Poly ICLC
This research is being done to see if the drug ruxolitinib is effective in reducing the symptoms caused by low-risk essential thrombocythemia (ET) and polycythemia vera (PV).
- This research study involves the study drug Ruxolitinib.
DRUG: Ruxolitinib
This phase II trial studies how well decitabine with ruxolitinib, fedratinib, or pacritinib works before hematopoietic stem cell transplant in treating patients with accelerated/blast phase myeloproliferative neoplasms (tumors). Drugs used in chemoth...
DRUG: Decitabine
DRUG: Ruxolitinib
DRUG: Fedratinib
OTHER: Questionnaire Administration
DRUG: Pacritinib
To learn if tasquinimod either alone or in combination with ruxolitinib can help to control PMF, post-PV MF, or post-ET MF.
DRUG: Ruxolitinib
DRUG: Tasquinimod
A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon alfa-2b-njft (P1101) in Adult Patients with Essential Thrombocythemia
DRUG: Ropeginterferon alfa-2b-njft (P1101)
A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients with PV
DRUG: P1101 (Ropeginterferon alfa-2b-njft)
DRUG: Ropeginterferon alfa-2b-njft (P1101)
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of INCB057643 as monotherapy or combination with ruxolitinib for participants with myelofibrosis (MF) and other myeloid neoplasms.
DRUG: INCB057643
DRUG: Ruxolitinib
This phase II trial studies how well ruxolitinib phosphate and azacytidine work in treating patients with myelofibrosis or myelodysplastic syndrome/myeloproliferative neoplasm. Ruxolitinib phosphate may stop the growth of cancer cells by blocking som...
DRUG: Azacitidine
OTHER: Laboratory Biomarker Analysis
DRUG: Ruxolitinib Phosphate
This study is being conducted to evaluate the safety, tolerability, dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of INCA033989 administered in participants with myeloprolif...
DRUG: INCA033989
This is a study evaluating the safety and efficacy of bomedemstat (MK-3543) compared with the best available therapy (BAT) in participants with essential thrombocythemia (ET) who have an inadequate response to or are intolerant of hydroxyurea.
The p...
DRUG: Bomedemstat
DRUG: Anagrelide
DRUG: Busulfan
DRUG: Interferon alfa/pegylated interferon alfa
DRUG: Ruxolitinib
This is an open label, multicenter, phase 2 trial of Canakinumab in patients with primary myelofibrosis (PMF), post essential thrombocythemia/polycythemia vera related MF (Post ET/PV MF). Eligible patients will receive Canakinumab administered as a s...
DRUG: Canakinumab
This study evaluates either KRT-232 or TL-895 in treatment naïve patients with myelofibrosis (MF)
The study will be conducted in 2 stages. Stage 1 will evaluate safety, tolerability, and efficacy of either KRT-232 (Arm 1) or TL-895 (Arm 2) in treatm...
DRUG: KRT-232
DRUG: TL-895
This phase II trial evaluates how a curcumin supplement (C3 complex/Bioperine) changes the inflammatory response and symptomatology in patients with clonal cytopenia of undetermined significance (CCUS), low risk myelodysplastic syndrome (LR-MDS), and...
PROCEDURE: Biospecimen Collection
PROCEDURE: Bone Marrow Aspiration
PROCEDURE: Bone Marrow Biopsy
DIETARY_SUPPLEMENT: Curcumin/ Demethoxycurcumin/Bisdemethoxycurcumin-containing Supplement
DIETARY_SUPPLEMENT: Piperine Extract (Standardized)
DRUG: Placebo Administration
OTHER: Questionnaire Administration
This phase I/II trial studies the best dose of ruxolitinib when given together with CPX-351 and to see how well they work in treating patients with accelerated phase or blast phase myeloproliferative neoplasm. Ruxolitinib may stop the growth of cance...
PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation
DRUG: Liposome-encapsulated Daunorubicin-Cytarabine
DRUG: Ruxolitinib
This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy or in combination with ruxolitinib in participants with MF who are transfusion-dependen...
DRUG: INCB000928
DRUG: ruxolitinib
This research study is studying a drug called Jaktinib as a possible treatment for Myelofibrosis.
DRUG: Jaktinib Hydrochloride Tablet
This is a phase I/II study evaluating the optimal dose of N-acetylcysteine (N-AC) in patients with myeloproliferative neoplasms (MPN).
DRUG: N-Acetylcysteine
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with myelofibrosis (MF) who no longer benefit from treatment with a JAK inhibitor. Inhibition of MDM2 is a novel mechanism of action in MF.
Th...
DRUG: KRT-232
DRUG: Best Available Therapy (BAT)
This is an open label, phase II study to assess the efficacy, safety, and tolerability of Reparixin in patients with DIPSS intermediate-2, or high-risk primary myelofibrosis (PMF), post essential thrombocythemia/polycythemia vera related MF (Post ET/...
DRUG: reparixin
The primary purpose of the study is to transition participants into an extension study to collect long-term safety and efficacy data. The study will include participants who are safely tolerating bomedemstat, receiving clinical benefit from its use i...
DRUG: Bomedemstat
This is a phase 1b/2 study of KRT-232 combined with ruxolitinib in subjects with MF who have a suboptimal response after at least 18 weeks of treatment with ruxolitinib. The primary objective of the study is to determine a recommended phase 2 dose (R...
DRUG: KRT-232
DRUG: Ruxolitinib
The purpose of this study is to characterize safety and to determine the Recommended Phase 2 Dose (RP2D\[s\]) and optimal dosing schedule(s) of JNJ-88549968, in part 1 (Dose Escalation); to characterize the safety of JNJ- 88549968 at RP2D(s), in part...
DRUG: JNJ-88549968
Get the latest thought leadership on your Juvenile Myelomonocytic Leukemia delivered straight to your inbox
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.
HealthTree Foundation is a qualified 501(c)(3) tax-exempt organization.
Copyright © 2024 HealthTree Foundation. All rights reserved.
Tax ID 45-5354811